CIP2A inhibits PP2A in human malignancies
- PMID: 17632056
- DOI: 10.1016/j.cell.2007.04.044
CIP2A inhibits PP2A in human malignancies
Abstract
Inhibition of protein phosphatase 2A (PP2A) activity has been identified as a prerequisite for the transformation of human cells. However, the molecular mechanisms by which PP2A activity is inhibited in human cancers are currently unclear. In this study, we describe a cellular inhibitor of PP2A with oncogenic activity. The protein, designated Cancerous Inhibitor of PP2A (CIP2A), interacts directly with the oncogenic transcription factor c-Myc, inhibits PP2A activity toward c-Myc serine 62 (S62), and thereby prevents c-Myc proteolytic degradation. In addition to its function in c-Myc stabilization, CIP2A promotes anchorage-independent cell growth and in vivo tumor formation. The oncogenic activity of CIP2A is demonstrated by transformation of human cells by overexpression of CIP2A. Importantly, CIP2A is overexpressed in two common human malignancies, head and neck squamous cell carcinoma (HNSCC) and colon cancer. Thus, our data show that CIP2A is a human oncoprotein that inhibits PP2A and stabilizes c-Myc in human malignancies.
Comment in
-
PP2A: unveiling a reluctant tumor suppressor.Cell. 2007 Jul 13;130(1):21-4. doi: 10.1016/j.cell.2007.06.034. Cell. 2007. PMID: 17632053 Review.
Similar articles
-
Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9157-62. doi: 10.1073/pnas.1317630111. Epub 2014 Jun 9. Proc Natl Acad Sci U S A. 2014. PMID: 24927563 Free PMC article.
-
CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.Oncogene. 2012 Sep 27;31(39):4266-78. doi: 10.1038/onc.2011.599. Epub 2012 Jan 16. Oncogene. 2012. PMID: 22249265
-
Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.Oncotarget. 2014 Jul 15;5(13):4581-602. doi: 10.18632/oncotarget.2127. Oncotarget. 2014. PMID: 25015035 Free PMC article. Review.
-
Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.Cancer Res. 2013 Nov 15;73(22):6548-53. doi: 10.1158/0008-5472.CAN-13-1994. Epub 2013 Nov 7. Cancer Res. 2013. PMID: 24204027 Review.
-
CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.Oral Oncol. 2012 Jul;48(7):585-93. doi: 10.1016/j.oraloncology.2012.01.012. Epub 2012 Feb 17. Oral Oncol. 2012. PMID: 22342571 Clinical Trial.
Cited by
-
CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.Tumour Biol. 2015 Jun;36(6):4777-83. doi: 10.1007/s13277-015-3129-4. Epub 2015 Jan 31. Tumour Biol. 2015. Retraction in: Tumour Biol. 2017 Apr 20. doi: 10.1007/s13277-017-5487-6. PMID: 25636449 Retracted.
-
CIP2A induces PKM2 tetramer formation and oxidative phosphorylation in non-small cell lung cancer.Cell Discov. 2024 Feb 6;10(1):13. doi: 10.1038/s41421-023-00633-0. Cell Discov. 2024. PMID: 38321019 Free PMC article.
-
Inhibition of protein methylesterase 1 decreased cancerous phenotypes in endometrial adenocarcinoma cell lines and xenograft tumor models.Tumour Biol. 2016 Sep;37(9):11835-11842. doi: 10.1007/s13277-016-5036-8. Epub 2016 Apr 5. Tumour Biol. 2016. PMID: 27048286
-
Intranasal immunization of lambs with serine/threonine phosphatase 2A against gastrointestinal nematodes.Clin Vaccine Immunol. 2013 Sep;20(9):1352-9. doi: 10.1128/CVI.00336-13. Epub 2013 Jun 12. Clin Vaccine Immunol. 2013. PMID: 23761655 Free PMC article.
-
Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.PLoS One. 2013;8(2):e55705. doi: 10.1371/journal.pone.0055705. Epub 2013 Feb 1. PLoS One. 2013. PMID: 23383345 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
